Classifications: anthelmintic; Therapeutic: anthelmintic
Pregnancy Category: B
600 mg tablets
Synthetic agent with broad-spectrum anthelmintic activity against all developmental stages of schistosomes and other trematodes
(flukes) and against cestodes (tapeworm). Increases permeability of parasite cell membrane to calcium. Leads to immobilization
of their suckers and dislodgment from their residence in blood vessel walls.
Active against all developmental stages of schistosomes, including cercaria (free-swimming larvae). Activity against other
trematodes (flukes) not fully understood; activity against cestodes (tapeworms) not clear but may be similar to that against
All stages of schistosomiasis (bilharziasis) caused by all Schistosoma species pathogenic to humans. Other trematode infections caused by Chinese liver fluke.
Lung, sheep liver, and intestinal flukes and tapeworm infections.
Hypersensitivity to drug; ocular cysticercosis. Safety in children <4 y is not established; women should not breast feed
on day of praziquantel therapy or for 72 h after last dose of drug.
Hepatic disease; cardiac arrhythmias; pregnancy (category B).
Route & Dosage
Adult/Child (>4 y): PO 60 mg/kg in 3 equally divided doses at 46 h intervals on the same day, may repeat in 23 mo after exposure
Adult/Child (>4 y): PO 75 mg/kg in 3 equally divided doses at 46 h intervals on the same day
Cestodiasis (Adult or Intestinal Stage)
Adult: PO 1020 mg/kg as single dose
Cestodiasis (Larval or Tissue Stage)
Adult: PO 50 mg/kg in 3 divided doses/d for 14 d
- Give dose with food and fluids. Tablets can be broken into quarters but should NOT be chewed.
- Advise patient to take sufficient fluid to wash down the medication. Tablets are soluble in water; gagging or vomiting because
of bitter taste may result if tablets are retained in the mouth.
- Treatment for cestodiasis (tapeworm) is followed by gentle purgation 2 h after drug administration to facilitate rapid removal
of tapeworms and ova.
- Store tablets in tight containers at <30° C (86° F).
Adverse Effects (≥1%)CNS: Dizziness, headache, malaise,
drowsiness, lassitude, CSF reaction syndrome
(exacerbation of neurological signs and symptoms such as seizures, increased CSF protein concentration, increased anticysticercal
IgG levels, hyperthermia, intracranial hypertension) in patient treated for cerebral cysticercosis. GI: Abdominal pain or discomfort with or without nausea;
vomiting, anorexia, diarrhea. Hepatic: Increased AST, ALT (slight). Skin:
Pruritus, urticaria. Body as a Whole:
Fever, sweating, symptoms of host-mediated immunologic response to antigen release from worms (fever, eosinophilia).
Diagnostic Test Interference
Be mindful that selected drugs may interfere with stool studies for ova and parasites: iron, bismuth, oil (mineral or castor), Metamucil (if ingested within 1 wk of test), barium, antibiotics, antiamebic and antimalarial drugs, and gallbladder dye (if administered within 3 wk of test).
can lead to therapeutic failure. Food: Grapefruit juice
(>1 qt/d) may increase plasma
concentrations and adverse effects.
Rapidly, 80% reaches systemic circulation. Peak:
13 h. Distribution:
Enters cerebrospinal fluid. Metabolism:
Extensively to inactive metabolites. Elimination:
Primarily in urine. Half-Life:
Assessment & Drug Effects
- Patient is reexamined in 2 or 3 mo to ensure complete eradication of the infections.
Patient & Family Education
- Do not drive or operate other hazardous machinery on day of treatment or the following day because of potential drug-induced
dizziness and drowsiness.
- Usually, all schistosomal worms are dead 7 d following treatment.
- Contact physician if you develop a sustained headache or high fever.